138 related articles for article (PubMed ID: 38579512)
1. The emicizumab-bridged ternary complex with activated factor IX and factor X evaluated by fluorescence resonance energy transfer.
Oda A; Takeyama M; Kitazawa T; Nogami K
Thromb Res; 2024 May; 237():108-111. PubMed ID: 38579512
[No Abstract] [Full Text] [Related]
2. Emicizumab, a bispecific antibody recognizing coagulation factors IX and X: how does it actually compare to factor VIII?
Lenting PJ; Denis CV; Christophe OD
Blood; 2017 Dec; 130(23):2463-2468. PubMed ID: 29042366
[TBL] [Abstract][Full Text] [Related]
3. Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens.
Kitazawa T; Esaki K; Tachibana T; Ishii S; Soeda T; Muto A; Kawabe Y; Igawa T; Tsunoda H; Nogami K; Shima M; Hattori K
Thromb Haemost; 2017 Jun; 117(7):1348-1357. PubMed ID: 28451690
[TBL] [Abstract][Full Text] [Related]
4. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity.
Kitazawa T; Shima M
Int J Hematol; 2020 Jan; 111(1):20-30. PubMed ID: 30350119
[TBL] [Abstract][Full Text] [Related]
5. Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis.
Rivas-Pollmar MI; Álvarez-Román MT; Butta-Coll NV; Martín Salces M; García-Barcenilla S; Jiménez-Yuste V
J Thromb Haemost; 2020 Sep; 18(9):2202-2204. PubMed ID: 32526092
[TBL] [Abstract][Full Text] [Related]
6. Effects and Interferences of Emicizumab, a Humanised Bispecific Antibody Mimicking Activated Factor VIII Cofactor Function, on Coagulation Assays.
Adamkewicz JI; Chen DC; Paz-Priel I
Thromb Haemost; 2019 Jul; 119(7):1084-1093. PubMed ID: 31064025
[TBL] [Abstract][Full Text] [Related]
7. Novel Insights and New Developments Regarding Coagulation Revealed by Studies of the Anti-Factor IXa (Activated Factor IX)/Factor X Bispecific Antibody, Emicizumab.
Yada K; Nogami K
Arterioscler Thromb Vasc Biol; 2020 May; 40(5):1148-1154. PubMed ID: 32237902
[TBL] [Abstract][Full Text] [Related]
8. Modified clot waveform analysis to measure plasma coagulation potential in the presence of the anti-factor IXa/factor X bispecific antibody emicizumab.
Nogami K; Matsumoto T; Tabuchi Y; Soeda T; Arai N; Kitazawa T; Shima M
J Thromb Haemost; 2018 Jun; 16(6):1078-1088. PubMed ID: 29645406
[TBL] [Abstract][Full Text] [Related]
9. Emicizumab, the bispecific antibody to factors IX/IXa and X/Xa, potentiates coagulation function in factor XI-deficient plasma in vitro.
Minami H; Nogami K; Yada K; Ogiwara K; Furukawa S; Soeda T; Kitazawa T; Shima M
J Thromb Haemost; 2019 Jan; 17(1):126-137. PubMed ID: 30444568
[TBL] [Abstract][Full Text] [Related]
10. Bispecific antibody mimicking factor VIII.
Nogami K
Thromb Res; 2016 May; 141 Suppl 2():S34-5. PubMed ID: 27207420
[TBL] [Abstract][Full Text] [Related]
11. Emicizumab prophylaxis among infants and toddlers with severe hemophilia A and inhibitors-a single-center cohort.
Barg AA; Avishai E; Budnik I; Levy-Mendelovich S; Barazani TB; Kenet G; Livnat T
Pediatr Blood Cancer; 2019 Nov; 66(11):e27886. PubMed ID: 31348595
[TBL] [Abstract][Full Text] [Related]
12. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
[TBL] [Abstract][Full Text] [Related]
13. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
[TBL] [Abstract][Full Text] [Related]
14. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
[TBL] [Abstract][Full Text] [Related]
15. Real-world case series and summary of current literature of infants and toddlers with severe hemophilia A with inhibitor on prophylaxis with emicizumab.
Garcia J; Zia A
Pediatr Blood Cancer; 2021 May; 68(5):e28942. PubMed ID: 33559300
[TBL] [Abstract][Full Text] [Related]
16. Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.
Muto A; Yoshihashi K; Takeda M; Kitazawa T; Soeda T; Igawa T; Sampei Z; Kuramochi T; Sakamoto A; Haraya K; Adachi K; Kawabe Y; Nogami K; Shima M; Hattori K
Blood; 2014 Nov; 124(20):3165-71. PubMed ID: 25274508
[TBL] [Abstract][Full Text] [Related]
17. Coagulation factor IX residues G4-Q11 mediate its interaction with a shared factor IX/IXa binding site on activated platelets but not the assembly of the functional factor X activating complex.
Ahmad SS; Wong MY; Rawala R; Jameson BA; Walsh PN
Biochemistry; 1998 Feb; 37(6):1671-9. PubMed ID: 9484238
[TBL] [Abstract][Full Text] [Related]
18. A hemophilia A mouse model for the in vivo assessment of emicizumab function.
Ferrière S; Peyron I; Christophe OD; Kawecki C; Casari C; Muczynski V; Nathwani A; Kauskot A; Lenting PJ; Denis CV
Blood; 2020 Aug; 136(6):740-748. PubMed ID: 32369559
[TBL] [Abstract][Full Text] [Related]
19. Bridging the Missing Link with Emicizumab: A Bispecific Antibody for Treatment of Hemophilia A.
Gelbenegger G; Schoergenhofer C; Knoebl P; Jilma B
Thromb Haemost; 2020 Oct; 120(10):1357-1370. PubMed ID: 32717759
[TBL] [Abstract][Full Text] [Related]
20. When innovation goes fast. The case of hemophilia.
Pilunni D; Montrasio L; Navarra P
Curr Opin Pharmacol; 2019 Apr; 45():95-101. PubMed ID: 31281026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
